DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02602600

GAP

CompletedPhase 4

Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels

Lead sponsor

Eva Prescott

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

33

actual

Study population

Cardiovascular disease, Obesity / overweight

Key I/E criteria

•BMI ≥25•Female

Primary endpoints

•Coronary Flow Reserve•Angina Symptoms

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02602600
Org study IDGAP

Timeline

Milestones

Study first posted2015-11-11estimated
Study start2015-11-19actual
Primary completion2017-04-18actual
Study completion2017-04-18actual
Last update posted2018-07-11actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Cardiovascular diseaseObesity / overweight

Eligibility

Who can enroll

Minimum age40 Years
Maximum age75 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•Women aged 40-75 with angina-like symptoms assessed by the Seattle Angina Questionnaire (SAQ).
•Women aged 40-75 with angina-like symptoms assessed by the Seattle Angina Questionnaire (SAQ).
•Referred for ischemic heart disease (IHD) assessment with no significant coronary stenosis (>50%) at coronary angiography or CT-angiography
•Impaired CFR assessed by echo Doppler flow (defined ratio≤2,5).
•BMI≥25kg/m2

Exclusion criteria

•Allergy to dipyridamole, theophyllamine or liraglutide
•Previous myocardial infarction or revascularization
•No episodes of chest pain within 6 months before inclusion
•Diabetes (reported, noted in journal or patient on antidiabetic medication)
•Other causes of chest discomfort deemed highly likely
•Left ventricular ejection fraction <45
•Significant valvular disease
•Congenital heart disease
•severe co-morbidity with limited life-expectancy< 1 year
•Severe asthma
•Severe chronic obstructive pulmonary disease
•Pregnancy (pregnancy test will be done at inclusion)
•No use of contraception although in child-bearing age. A woman is regarded fertile, following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. The birth control methods considered safe and effective includes combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD) and intrauterine hormone-releasing system ( IUS). Women in child-bearing age will have to use one of the above mentioned contraceptive methods from inclusion in the study until the end of study participation.
•physical or mental disability
•active cancer
•significant renal (eGRF<30) or hepatic co-morbidity
•chronic alcohol abuse
•atrial fibrillation
•Atrio-ventricular block>1st degree
•chronic or previous acute pancreatitis
•inflammatory bowel disease
•history of thyroid carcinoma
•participation in other clinical trial if relevant for the present study.
•Language- or other barrier to giving informed consent
•No signed informed consent

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Other (unclassified)
2
Cardiometabolic biomarkers
1
Patient-reported / QoL
1

Weight & body composition

2 endpoints
Secondary/protocol endpoint

Change in body weight

Time frame:Assessed at baseline, week 4 and week 18

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in body composition

Time frame:Assessed before and after treatment (week 4 and week 18)

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Change in endothelial function

Time frame:Assessed at baseline, week 4 and week 18

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

Change from baseline in Angina Symptoms

Time frame:Assessed at baseline, week 4 and week 18

change from baseline, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Change from baseline in Coronary Flow Reserve

Time frame:Assessed at baseline, week 4 and week 18

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in cardiac function

Time frame:Assessed at baseline, week 4 and week 18

change from baseline, descriptive

Publications (23)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.